By Rachel Cooper, City Reporter (Pharmaceuticals) Published: 6:16PM GMT 02 March 2010
AstraZeneca
Last month, the Anglo-Swedish drug maker, that is confronting obvious expiry on a dual of the top-earning drug this year, pronounced it was to renovate the operations with the loss of up to 8,000 jobs , together with up to 1,800 in research.
On Tuesday, it suggested where the mattock will fall, together with the closure of a investigate site at Charnwood in Leicestershire, that employs 1,200 people, and a not as big trickery in Cambridge.
AstraZeneca to cut a serve 8,000 jobs to condense costs AstraZeneca eyes uninformed share buy-back intrigue after stellar 2009 AstraZeneca to make known tie-up with Dako AstraZeneca buys antibiotics organization Novexel AstraZeneca increase burst on hog influenza vaccine Doctoring the Mind: Why Psychiatric Treatments Fail by Richard Bentall: examinationBritain"s second-largest curative association told staff on Tuesday that it would go on investigate in all stream care areas, but inside of these sectors, it would stop find efforts in around 10 specific diseases.
Discovery is to be forsaken in thrombosis, poison reflux, ovarian and bladder cancers, systemic scleroderma and hepatitis C.
Like GlaxoSmithKline, that voiced last month it was to stop researching antidepressants since of capricious returns, AstraZeneca is additionally to stop find in basin and anxiety, as well as schizophrenia and bipolar disorders.
Anders Ekblom, head of growth at AstraZeneca said: "AstraZeneca"s vital joining to investing in innovative investigate and growth is as transparent as ever."
He combined there was a stability need to conform the organization in expectation of destiny challenges.
The association combined that where possible, it would re-deploy staff.
No comments:
Post a Comment